

## Alector Corporate Overview

January 2025

## **Forward-Looking Statement**

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potentially," "predict," "should," "will" or the negative of these terms or other similar expressions. Forward-looking statements contained in this presentation also include, but are not limited to, statements regarding: our future financial condition, including the sufficiency of cash to fund operations through 2026; results of operations; business strategy and plans; the beneficial characteristics, safety, efficacy, and therapeutic effects of our product candidates; our plans, timelines and expectations related to our product candidates and our other clinical and preclinical programs, including with respect to the availability of data, the initiation of future clinical trials and plans and expectations regarding planned regulatory filings with respect to such programs; expectations regarding the timing and financial benefit of our collaborations; and objectives of management for future operations, as well as statements regarding industry trends.

We, Alector, Inc. ("Alector"), have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: Alector's plans relating to its research programs, preclinical and clinical development programs and the development and manufacturing of its product candidates and blood-brain barrier technology platform; the ability of Alector's clinical trials to demonstrate safety and efficacy of its product candidates, and other positive results; the timing and focus of Alector's clinical trials, and the reporting of data from those trials, including the anticipated timing and detail regarding the release of data for INFRONT-3 and PROGRESS-AD; Alector's plans relating to commercializing its product candidates, if approved, including the geographic areas of focus and sales strategy; the expected potential benefits of strategic collaborations with third parties and Alector's ability to attract collaborators with development, regulatory and commercialization expertise; Alector's estimates of the number of patients in the United States, the European Union and world-wide who suffer from the diseases it is targeting and the number of patients that will enroll in its clinical trials; the anticipated timing of enrollment in its clinical trials; the size of the market opportunity for Alector's product candidates in each of the diseases it is targeting; Alector's ability to expand its product candidates into additional indications and patient populations; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy, and therapeutic effects of Alector's product candidates; the timing or likelihood of regulatory filings and approvals, including Alector's expectation to seek special designations, such as orphan drug designation, for its product candidates for various diseases; Alector's ability to obtain and maintain regulatory approval of its product candidates; Alector's plans relating to the further development and manufacturing of its product candidates, including additional indications that it may pursue; existing and future regulations and regulatory developments in the United States and other jurisdictions; Alector's reliance on third parties to conduct clinical trials of its product candidates, and for the manufacture of its product candidates for preclinical studies and clinical trials; the impact of worldwide economic conditions, including macroeconomic downturns stemming from increased inflation, supply chain and other economic impacts of the coronavirus (COVID-19) pandemic and geopolitical events on our business; and the other risks, uncertainties and assumptions discussed in the public filings we have made and will make with the Securities and Exchange Commission ("SEC"). These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

This presentation also contains results based on data from our clinical trials. These clinical trials are ongoing and this presentation does not speak to, and you should make no assumptions about, any additional data. In addition, the information we have chosen to publicly disclose regarding our product candidates has been selected from a more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise. If the initial data that we report differ from updated, late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.

This presentation discusses certain investigational therapeutic agents which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of our product candidate for the therapeutic use for which it is being studied.

This presentation contains statistical data based on independent industry publications or other publicly available information, as well as other information based on our internal sources. We have not independently verified the accuracy or completeness of the data contained in these industry publications and other publicly available information. Accordingly, we make no representations as to the accuracy or completeness of that data.

Except as required by law, we undertake no obligation to update any statements in this presentation for any reason after the date of this presentation. We have filed Current Reports on Form 8-K, Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, and other documents with the SEC. You should read these documents for more complete information about us. You may obtain these documents for free by visiting EDGAR on the SEC website at <u>www.sec.gov</u>.



### **Bold Vision**

### A world where we made degenerative brain disorders history

#### **Innovative Science**

3R Strategy: Remove, Replace, Restore Targeting 2 INDs in 2026

### Novel Clinical Programs

Targeting Pivotal Ph 3 data in FTD Q4 2025 Targeting Ph 2 enrollment completion in AD in mid-2025

### **Advanced Technologies**

Versatile Alector Brain Carrier (ABC) technology platform

#### Well Resourced

Experienced leadership and strong financial resources


### **Global Partnership**

Profit-sharing collaboration with GSK for multiple PGRN product candidates



## Innovative Science with 3R Strategy of Remove, Replace, Restore

Remove toxic proteins, Replace critical deficient proteins, and Restore immune and nerve cells to normal functioning



Leveraging our drug development expertise and proprietary technology to advance a curated portfolio of programs that address genetically-validated targets.




## Alector Brain Carrier (ABC): Enhanced Delivery of Biologics Across the BBB

Supports portfolio of genetically validated programs for neurodegenerative diseases

#### **Blood Brain Barrier (BBB)**

- Maintains homeostasis and protects by restricting access
- Poses a challenge for how much drug gets into the brain




Alector Brain Carrier (ABC) is a proprietary, versatile BBB technology platform designed to overcome challenges of drug delivery to the CNS

- Selectively applied to our pipeline
- Aims to improve outcomes while reducing costs by enhancing delivery of therapeutics to achieve deeper brain penetration at lower doses
- Initial focus is on two key targets: transferrin receptor (TfR) and CD98hc
- Unique versatility and tunability may allow for the delivery of a range of cargos, including antibodies, proteins, enzymes, and nucleic acids
- May facilitate more convenient subcutaneous delivery

## Development Portfolio: Advancing Late-Stage Programs with Established Partner, Supported by Genetically Validated Research Portfolio and Proprietary ABC Platform





#### \$457.2 MILLION<sup>1</sup> IN CASH PROVIDES RUNWAY THROUGH 2026

**alector**<sup>-</sup> 1. Cash, cash equivalents, and marketable securities as of September 30, 2024, were \$457.2 million.

FTD-*GRN* = frontotemporal dementia with a progranulin gene mutation, AD = Alzheimer's disease, PD= Parkinson's disease, BD = Lewy body dementia, ABC = Alector Brain Carrier

Property of Alector 6






## PGRN Programs

## Latozinemab and AL101: Pioneering Approach to Elevating Progranulin Levels With Potential to Enhance Microglial and Neuronal Function and Treat FTD and AD

#### PGRN: Genetic and Biologic Rationale

- Genetics: Mutations in GRN, which encodes PGRN, are deleterious.
  - Homozygous (100% LOF): Neuronal ceroid lipofuscinosis with onset <25 years of age, 100% penetrance.
  - Heterozygous (50% LOF): Reduce progranulin levels to 50% of normal; Frontotemporal dementia with onset ~58 years of age, >90% penetrance.
  - Non-coding mutations (~10-20% LOF): Increase risk for ALS, FTD, AD, PD.
- Biology: PGRN is a critical immune regulator, neuronal survival factor and a lysosomal chaperone.

#### Latozinemab and AL101: PGRN Elevating Program



Latozinemab (AL001) and AL101 elevate PGRN levels by blocking sortilin (SORT1), a degradation receptor for PGRN



# Frontotemporal Dementia (FTD): A Rapidly Progressive Form of Dementia, with No Approved Treatment



Tommy Nash Jr., with his daughter, Alyssa Nash. Tommy was diagnosed with FTD at 38 years old.<sup>1</sup>

1. With permission from Tommy Nash Jr. and Alyssa Nash, May 2023 Greaves et al. *J Neurol.* 2019;266:2075-2086. Taylor RT, et al. *Pract Neurol.* 2019:72-77. Kansal K, et al. *Dement Geriatr Cogn Disord.* 2016;41:109-122. Boeve BF, et al. *Brain.* 2006;129:3103-3114. UCSF Weill Institute for Neurosciences Memory and Aging Center: Familial FTD

alector

**Prevalence:** Most common cause of dementia under age 60

#### Progression:

- Rapid progression of memory impairment, other cognitive functions
- Life expectancy after diagnosis is 7-10 years

#### **Diagnosis:**


- Compulsive behavior, lack of restraint, apathy, anxiety, and aphasia
- Symptoms typically begin between the ages of 45-64 years old
- Frequently misdiagnosed as AD, depression, PD, or psychiatric condition
- **Treatment:** No approved treatments to cure or slow progression of FTD

#### Forms:

- Sporadic FTD occurs without a clear familial or inherited pattern
- Genetic FTD occurs due to autosomal dominant mutations in one of three genes: *GRN, C9orf72* or *MAPT*

## **INFRONT-2:** Phase 2 Trial with Latozinemab in FTD

(FTLD) sum of boxes (SB)



## **INFRONT-2: Clinical Outcome Assessments Supported by Biomarkers in FTD-GRN**

Key biomarkers and clinical outcome assessments reflect underlying disease activity in FTD-GRN patients


TARGET ENGAGEMENT	BIOMARKERS OF DISEASE ACTIVITY				CLINICAL BENEFIT
PGRN (Plasma and CSF)	Lysosomal Dysfunction	Inflammation	Brain Health	Brain Atrophy	Clinical Outcome Assessments
PGRN	e.g. CTSD, LAMP1	e.g. C1QB	GFAP	MRI	CDR <sup>®</sup> plus NACC FTLD-SB
CSF and plasma PGRN levels	Dysfunctional lysosomes are hallmarks of FTD- <i>GRN</i>	Elevation of complement proteins occurs in FTD- <i>GRN</i>	Elevation of GFAP is a hallmark of FTD- <i>GRN</i> correlates with cognitive decline	Accelerated brain tissue loss is a hallmark of FTD- <i>GRN</i> and correlates with cognitive decline	FDA approvable endpoint for measuring clinical decline in FTD




CTSD = cathepsin D; LAMP1 = lysosomal associated membrane protein 1; C1QB = complement C1q B chain; GFAP = glial fibrillary acidic protein CDR<sup>®</sup> plus NACC FTLD-SB = Clinical Dementia Rating (CDR) dementia staging instrument plus National Alzheimer's Coordinating Center (NACC) behavior and language domains frontotemporal lobar degeneration (FTLD) sum of boxes (SB)

# INFRONT-2: Latozinemab Restores PGRN in Plasma and CSF to Levels Seen in Healthy Volunteer Age-Matched Controls

#### ACHIEVED PGRN RESTORATION IN FTD-GRN PARTICIPANTS






**PGRN CSF Concentration** 

Data cut-off June 15, 2021 Mean +/- SEM Source: AAIC 2021.

alector

## INFRONT-2: Latozinemab Treatment Decreases Glial Fibrillary Acidic Protein (GFAP) Levels Towards Range Seen in Asymptomatic Carriers of FTD-*GRN* Mutation

#### **BIOMARKERS OF DISEASE ACTIVITY – ASTROGLIOSIS**




## **INFRONT-2: Encouraging Trends Across Biomarkers Of Disease Activity**

#### SYMPTOMATIC FTD-GRN PARTICIPANTS AT 12 MONTHS IN OPEN LABEL TRIAL

#### LYSOSOMAL AND INFLAMATORY BIOMARKERS

#### **BRAIN VOLUME CHANGES BIOMARKERS**



Normalization of lysosomal and inflammatory biomarkers


Markers	Latozinemab Baseline (N=9)	Latozinemab 6 months (N=8)	Latozinemab 12 months (N=8)	Age-matched procured control (N=44)
CTSD (fm/μL)	5.2 (1.16)	3.8 (0.57)	3.1 (0.21)	3.4 (0.08)
LAMP1 (fm/µL)	0.6 (0.12)	0.4 (0.06)	0.4 (0.043)	0.4 (0.01)
C1QB (fm/µL)	0.7 (0.12)	0.6 (0.07)	0.5 (0.02)	0.5 (0.02)

Mean +/- SEM

CTSD = cathepsin D protein




LAMP1= lysosomal-associated membrane protein 1 C1QB = gene that encodes the B-chain polypeptide of serum complement subcomponent C1q



\* n=8 for Whole Brain, n=7 for TBM measures (TBM measures were not available for one GENFI2 participant). One GENFI2 subject was excluded from the analysis as the patient displayed cortical volume increases (2.58% annual volume increase in the FT cortex) indicating image analysis artifact

# INFRONT-2: Preliminary Data Suggests Latozinemab May Slow Disease Progression in FTD-GRN Participants Compared to Matched Historical Controls

#### CLINICAL MEASURE



#### **CDR® plus NACC FTLD-SB**

GENFI2 refers to the longitudinal FTD registry dataset


Property of Alector 15

NCT03987295

Phase 2 data presented at CTAD 2021 and ADPD 2022

alector

## **INFRONT-3: Ongoing Pivotal Phase 3 Study with Latozinemab**





"At risk" = GRN carriers who are pre-symptomatic and meet a pre-specified NfL threshold for enrollment in the Phase 3 trial; CDR® plus NACC FTLD-SB = Clinical Dementia Rating Dementia Staging Instrument plus National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration Behavior and Language Domains Sum of Boxes; CGI-S = Clinician's Global Impression-Severity; CGI-I = Clinician's Global Impression-Improvement; FRS = Frontotemporal Dementia Rating Scale; RBANS = Repeatable Battery for the Assessment of Neuropsychological Status

# INFRONT-3 Baseline Characteristics: Data Suggest a Representative Study Population for Testing Effects of Latozinemab in FTD-*GRN* Compared Against Registry Data

#### **INFRONT-3 Baseline Age**

	At-Risk	Symptomatic	Total
	(n=16)	(n=103)	(N=119)
Age, mean (min, max), years	59.2 (37, 79)	62.5 (48, 85)	62.1 (37, 85)

#### **INFRONT-3 Baseline Clinical Characteristics**<sup>a</sup>

	At-Risk (n=16)	Symptomatic (n=103)	Total (N=119)
CDR <sup>®</sup> plus NACC FTLD-GS, n (%)			
0	15 (93.8)	0	15 (12.6)
0.5	1 (6.3)	23 (22.3)	24 (20.2)
1	0	49 (47.6)	49 (41.2)
2	0	31 (30.1)	31 (26.1)
CDR <sup>®</sup> plus NACC FTLD-SB, n	16	103	119
Mean (SD)	0.0 (0.1)	6.9 (4.1)	6.0 (4.4)
NfL concentration (pg/mL), n	12	87	99
Mean (SD)	16.0 (9.7)	73.0 (41.5)	66.1 (43.3)
Median (min, max)	14.4 (7.8, 42.9)	66.9 (6.5 <i>,</i> 190.0)	61.7 (6.5, 190.0)

#### Symptomatic FTD-*GRN* participants from ALLFTD and GENFI Registry Studies (n=84):<sup>1</sup>

#### Mean age of 63.7 years (SD: 8.8)

#### Mean CDR<sup>®</sup> plus NACC FTLD-SB score of 9.19 (SD: 6.53)

#### Mean plasma NfL geometric mean: 56.8 pg/mL

CDR® plus NACC FTLD-GS, Clinical Dementia Rating scale plus National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration Global Score; CDR® plus NACC FTLD-SB, Clinical Dementia Rating scale plus National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes; NfL, neurofilament light chain; SD, standard deviation

## AL101/GSK4527226: Developed to Align with Needs of Larger Indications (AD)

PGRN: Genetic and Biologic Rationale for AD


- **Genetics:** PGRN deficiency is a risk for AD.
- **Biology:** Modulation of PGRN in AD disease models.
  - PGRN ablation exacerbates AD in disease models.
  - PGRN overexpression is protective in AD disease models.

- AL101/GSK4527226 AD Program
- **Phase 1:** Completed in healthy volunteers.
- **Phase 2:** Received IND clearance from FDA in AD.
- **Phase 2:** Reached approximately 75% of its target enrollment of 282 participants, with enrollment completion anticipated in mid-2025.



Mendsaikhan, A., et al. Characterization of lysosomal proteins Progranulin and Prosaposin and their interactions in Alzheimer's disease and aged brains: increased levels correlate with neuropathology. *acta neuropathol commun 7, 215 (2019). The breakdown of clinical diagnoses among ARTFL FTD mutations carriers. [Courtesy of Adam Boxer.] <u>https://www.alzforum.org/print-series/1093496</u>; Bellenguez C, Küçükali F, Jansen I, et al. New insights on the genetic etiology of Alzheimer's and related dementia. medRxiv; 2020.* 


## AL101/GSK4527226: Rationale for PGRN-Elevating Drugs in Alzheimer's Disease



Source(s): https://doi.org/10.1101/2020.10.01.20200659 (Left); ARTFL Diagnoses. The breakdown of clinical diagnoses among ARTFL FTD mutations carriers. [Courtesy of Adam Boxer.] https://www.alzforum.org/print-series/1093496 (Right); Source: doi: alector https://doi.org/10.1101/2020.10.01.20200659; Acta Neuropathologica Communications volume 7, Article number: 215 (2019); Nat Med. 2014; Nat Med. 2014 Oct; 20(10): 1157-1164.

## AL101/GSK4527226: Genetic Evidence Supports Increasing PGRN Levels in AD

#### COMMON GRN VARIANT RS5848 T ALLELE IS ASSOCIATED WITH (A) AD RISK AND (B) DECREASED PGRN LEVELS IN CSF AND PLASMA



Property of Alector


1.20

"Genetic evidence supports therapeutic hypothesis of increasing progranulin levels for Alzheimer's Disease," GSK, AAIC 2024

alector

## AL101/GSK4527226: PROGRESS-AD Study Design

#### PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AL101/GSK4527226 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE



#### Key inclusion criteria

- Age 50-85 years, inclusive
- · Diagnosis of MCI due to AD up to mild AD dementia
- Amyloid positivity (by PET or CSF)

#### **Primary endpoint**

Change from Baseline in CDR-SB across Weeks 52, 64 and 76.

#### Key secondary endpoints

Change from Baseline across Weeks 52, 64 and 76 for iADRS, ADAS-Cog14, ADCS-iADL, ADCS-ADL-MCI, ADCOMS

Biomarkers: Amyloid PET, Tau PET, CSF and Plasma



## Latozinemab and AL101: Currently Partnered in a Collaboration Agreement with GSK

## Latozinemab and AL101

\$700M upfront (2021 and 2022)
\$1.5B+ in potential milestone payments
U.S. 50-50 profit share and co-commercialization
Tiered double-digit royalties ex-U.S.
\$160 million for first commercial sale in the U.S.
\$90 million for first commercial sale in at least
two of the following countries: France, Germany,
Italy, Spain, or the UK

Latozinemab INFRONT-3 pivotal Phase 3 data anticipated by Q4 2025 AL101 PROGRESS-AD Phase 2 enrollment completion expected in mid-2025



GSK

## ABC Technology




## **Alector Brain Carrier (ABC): Designed for Effective Brain Delivery**

#### Alector Brain Carrier (ABC)

- Enables the potential to widen the therapeutic window while lowering the costs of goods and facilitating convenient delivery options
- Versatile: Tailored for a range of therapeutic cargos including antibodies, proteins, enzymes, and nucleic acids
- **Tunable:** Broad affinity toolbox for optimal therapeutic cargo-ABC pairing
- Translatability: Supports potential for rapid progression to the clinic

#### **Receptor-Mediated Transcytosis**





## TfR and CD98hc: Offer Distinct Advantages for Cargo Selection

Target	Receptor Function	CNS Cell Expression	BBB Expression Level	Localization	Trafficking of ABC in Brain Endothelial Cell Line
Transferrin Receptor (TfR)	Iron transport receptor	Neuronal, microglia	High	Punctate, endolysosomal	DAPI TFR-ABC
CD98hc/ Slc3a2	Amino acid transport complex	Broad	High	Broad, cell surface	DAPI CD98hc-ABC


Therapeutic cargo will also impact target cell localization and trafficking

hCMEC/D3 cells; 2h incubation, hulgG detection; 40x



## **TfR-ABC: Drives Widespread Biodistribution in Mouse Brain**

- Strong staining of neurons across brain regions due to combination of TfR and Target 3 binding
- Biodistribution of TfR-ABC molecule is highly cargo-dependent




Treated without ABC Treated with TfR-ABC Target 3-IgG Target 3-TfR Deep Brain Penetration with TfR-ABC Hippocampus Hippocampus




Anti-human antibody visualized post 50mg/kg iv dosing

# CD98hc-ABC: Facilitates Brain Uptake to Parenchymal Fraction in hCD98hc ECD KI+/+ Mice

Antibody level in vessel-depleted brain fraction post 20mg/kg iv dose, n=3/group



## Anti-human antibody visualized 7d post-iv dosing (20 mg/kg)




## **Proprietary Portfolio**



### **ADP037-ABC: Brain-Penetrant Anti-Aß Antibody**

Vision	Combine Alector's anti-Aß antibody with our proprietary ABC to facilitate rapid clearance of Aß plaques with minimal ARIA and the potential for subcutaneous delivery.
Rationale and Strategy	<ul> <li>Current anti-Aβ antibodies are modestly effective, require high-doses to remove Aβ, and are associated with amyloid-related imaging abnormalities (ARIA)</li> <li>Develop brain-penetrant antibody that specifically binds to a PyrGlu3 Aβ epitope</li> <li>Demonstrate effective plaque binding and removal with minimal ARIA</li> </ul>

#### ADDING BBB SHUTTLE REDUCED ARIA FOR ANTI-A $\beta$ ANTIBODY



Trontinemab is the	
gantenerumab	
antibody with	
transferrin receptor	
BBB binding domain	

		Comple	eted <sup>1</sup>		Not yet complete	d (interim data) <sup>1</sup>
			RT 1 :60)		PART 2 (n=95)	
Total number of participants with event (%)	Cohort 1 0.2 mg/kg or Pbo (n = 14)	Cohort 2 0.6 mg/kg or Pbo (n = 14)	Cohort 3 1.8 mg/kg or Pbo (n = 16)	Cohort 4 3.6 mg/kg or Pbo (n = 16)	Cohort 3 1.8 mg/kg or Pbo (n = 60)	Cohort 4 3.6 mg/kg or Pbc (n = 35)
ARIA-E <sup>2</sup>	0	0	1 (6.3%)	0	2 (3.3%)	0
<b>ARIA-H</b> Microhemorrhage Superficial siderosis	0 0 0	0 0 0	1 (6.3%) 0 1 (6.3%)	0 0 0	4 (6.7%) 2 (3.3%) 2 (3.3%)	2 (5.7%) 2 (5.7%) 0
Concurrent ARIA-E + ARIA-H	0	0	0	0	0	0

## **ADP050-ABC: Brain-Penetrant GCase Replacement Therapy**

Vision	Combine Alector-engineered GCase enzyme with our proprietary ABC for maximal GCase replacement in <i>GBA</i> mutation carriers with Parkinson's disease (PD) and Lewy body dementia (LBD).		
Rationale and Strategy	• Engineer an active, stable, developable, minimally immunogenetic GCase enzyme compatible with ABC format		
GBA1 Gene Mutations Are a Major Risk Factor for Neurodegenerative Diseases			
	Parkinson's Disease (PD) <sup>8</sup>	Lewy Body Dementia (LBD) <sup>8</sup>	Gaucher Disease (GD) <sup>9</sup>



alector

Braak stage 1 Braak stage 2 Braak stage 3 Braak stage 4 Braak stage 5 Braak stage 6

~10 million patients worldwide<sup>1</sup>

- 5-15% are *GBA1* mutation carriers<sup>2</sup>
- Activity is reduced in non-carriers<sup>2</sup>
- Potential to use GCase ERT in sporadic PD



Olfactory only stage Amygdala predominant stage Brainstem stage Limbic/transitional stage Neocortical stage

- ~5-8 million patients worldwide<sup>3</sup>
- 3-30% are GBA1 mutation carriers<sup>4</sup>
- Activity is reduced in non-carriers<sup>4</sup>
- Potential to use GCase ERT in sporadic LBD

100 × 100

- ~125,000 patients worldwide<sup>5</sup>
- GBA1 mutations are causal
- GD type 1 have increased risk of PD<sup>6</sup>
- GD type 2 and 3 are neuronopathic<sup>7</sup>

#### 1. Parkinson's Foundation Statistics

2. Smith L, Schapira AHV. GBA Variants and Parkinson Disease: Mechanisms and Treatments. *Cells*. 2022 Apr 8;11(8):1261.

#### 3. Alzheimer's Disease International, Dementia with Lewy Bodies

4. Nalls MA, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. *JAMA Neurol.* 2013 Jun;70(6):727-35.


5. Meikle PJ, et al. Prevalence of lysosomal storage disorders. JAMA. 1999 Jan 20;281(3):249-54.

- 6. Bultron G, et al. The risk of Parkinson's disease in type 1 Gaucher disease. *J Inherit Metab Dis*. 2010 Apr;33(2):167-73. 7. National Gaucher Foundation, Gaucher Disease Types 2 and 3
- 8. Used with permission of Springer Nature BV, from Brain regions susceptible to alpha-synuclein spreading, Guo, YJ et al, 27, 1997; permission conveyed through Copyright Clearance Center, Inc.
- 9. Stirnemann J et al. Int J Mol Sci. 2017 Feb 17;18(2):441. (https://creativecommons.org/licenses/by/4.0/).


## **ADP056: Alector's Reelin Modulator**

Vision	Develop a reelin modulator that replicates and exceeds the protective effects of the gene mutation.
Rationale and Strategy	<ul> <li>Reelin gain-of-function variant has been shown to protect against familial AD through a novel mechanism of action that uncouples Aβ pathology from tau pathology</li> <li>Reelin is a large multimeric secreted protein consisting of 3,460 amino acids (~390kDa as a monomer), making it unsuitable for use as a drug</li> <li>Develop a stable, long half-life reelin modulating drug that replicates the protective effects of the genetic variant</li> </ul>

High brain amyloid and limited tau observed in individuals with protective reelin mutation and at risk for familial AD




#### RELN-H3447R=RELN-COLBOS



## ADP063-ABC: Brain-Penetrant Anti-Tau Antibody

Vision	Combine Alector's anti-tau antibody in development with our proprietary ABC to block the spread of tau aggregates, with the potential for subcutaneous delivery and combination with anti-Aβ drugs.
Rationale and Strategy	<ul> <li>Pathological tau levels are directly associated with Alzheimer's disease</li> <li>Tau mutations lead to frontotemporal dementia</li> <li>The most promising anti-tau antibody targets the tau microtubule binding region (MTBR) and shows promising results in human trials (~60% reductions in MTBR-tau243, p-tau217)</li> <li>Target a first-in-class therapeutic by developing anti-tau MTBR antibodies compatible with ABC to enable deep and effective brain penetration</li> </ul>

CSF-MTBR-tau243 dropped by ~ 40% to 70% within the first three months in response to treatment with E2814 a naked anti-tau antibody in people with dominantly inherited AD




- Five participants with AD were treated with Eisai's anti-tau antibody E2814, with MTBR-tau-243 levels measured for each.
- Each colored line represents an individual participant.



## **ADP064-ABC: Brain-Penetrant Tau siRNA**

Vision	Combine potent anti-tau siRNA with our proprietary ABC to enable rapid blockade of tau mRNA synthesis, with the potential for peripheral delivery and combination with anti-Aβ drugs.
Rationale and Strategy	<ul> <li>Pathological tau levels are directly associated with Alzheimer's disease</li> <li>Tau mutations lead to frontotemporal dementia</li> <li>Intrathecally delivered tau ASO was shown to reduce CSF tau by 60% as well as tau tangles (ADPD 2023 BIIB080).</li> <li>Develop tau-siRNA with ABC to enable deep and effective brain penetration and peripheral delivery</li> </ul>

CSF concentrations of p-tau protein dropped by ~50% in response to Biogen's naked tau-targeting antisense oligonucleotide in people with mild AD



Mummery, C.J., et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. *Nat Med* 29, 1437–1447 (2023).

Property of Alector 33

# Alector Value Proposition: Aims to Deliver Innovation That Makes Degenerative Brain Disorders History

#### Accomplishments to Date

Pioneering firsts for patients

- Investigational latozinemab (AL001) first anti-SORT1 molecule in FTD-GRN<sup>1</sup>
- Latozinemab granted Orphan Drug Designation for FTD from FDA and EMA as well as Breakthrough Therapy and Fast Track designations for FTD-GRN from FDA
- Enrollment ongoing in AL101/ GSK4527226 AD Ph 2
- Pipeline of first- and best-in-class approaches for brain disorders<sup>1</sup>

#### Goals for Next 3 Years

Aim to deliver firsts for patients

- **Deliver data** for latozinemab FTD-*GRN* pivotal P3
- Deliver data for AL101/GSK4527226 AD P2
- **Deliver blood brain barrier** technology platform to enhance our novel programs
- Deliver 4+ leads for IND enabling studies and share initial clinical data to drive development progress

#### Goals for Next 3+ Years

Aim to make brain disorders history

- Obtain regulatory approval and commercialize latozinemab in FTD-GRN\*
- Share P2 and P3 clinical data for proprietary programs
- Continue to advance our science from research to the clinic with multiple INDs for genetically validated programs

#### \$457.2 MILLION<sup>2</sup> IN CASH PROVIDES RUNWAY THROUGH 2026



Alector is not aware of any other PGRN-elevating candidates in a Phase 3 trial for FTD or in a Phase 2 or Phase 3 trial for AD as of Jan. 2025.
 Cash, cash equivalents, and marketable securities as of September 30, 2024, were \$457.2 million.
 AL001 (latozinemab) and AL101 are investigational therapies.

\*Assuming positive Phase 3 data



## Thank You